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Abstract: The primary immunogenic component of the currently approved anthrax vaccine 
is  the  protective  antigen  (PA)  unit  of  the  binary  toxin  system.  PA-specific  antibodies 
neutralize anthrax toxins and protect against infection. Recent research has determined that 
in humans, only antibodies specific for particular determinants are capable of effecting 
toxin neutralization, and that the neutralizing epitopes recognized by these antibodies are 
distributed throughout the PA monomer. The mechanisms by which the majority of these 
epitopes effect neutralization remain unknown. In this report we investigate the process by 
which  a  human  monoclonal  antibody  specific  for  the  amino-terminal  domain  of  PA 
neutralizes lethal toxin in an in vitro assay of cytotoxicity, and find that it neutralizes LT by 
blocking the requisite cleavage of the amino-terminal 20 kD portion of the molecule (PA20) 
from the remainder of the PA monomer. We also demonstrate that the epitope recognized 
by this human monoclonal does not encompass the 166RKKR169 furin recognition sequence 
in domain 1 of PA. 
Keywords: anthrax; Bacillus anthracis; antibody epitope; paratope; human monoclonal 
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1. Introduction 
The Bacillus anthracis binary toxins are major virulence factors in anthrax infection [1,2]. The cell 
surface recognition element of this toxin system is an 83-kDa secreted protein known as protective 
antigen (PA). PA is the primary immunogenic component in the anthrax vaccine currently licensed for 
use  in  the  United  States  (BioThrax™  or  AVA,  Emergent  Biosystems),  and  ongoing  attempts  to 
develop a “next generation” anthrax vaccine are relying on a recombinant form of PA as the sole 
immunogenic  constituent.  Efforts  towards  the  design  of  more  efficacious  anthrax  vaccines  would 
benefit  from  a  more  thorough  understanding  of  both  the  biology  of  this  protein  toxin,  and  the 
immunobiology of its interaction with the immune system of the vaccinated or infected host. 
We have used repertoire profiling to de-convolute the polyclonal human antibody response to PA 
into its component PA-specific paratopes [3–6]. We find that PA activates a diverse collection of B 
cells which utilize a variety of variable heavy, variable light, diversity, and joining gene segments to 
form  PA-specific  antibody  [6].  Descendants  of  these  clones  undergo  expansion,  somatic 
hypermutation, and class switch recombination. Together, the ability of PA to both recruit a diverse  
B-cell population and drive significant somatic maturation gives rise to a complex serum antibody 
response  composed  of  multiple  sequence-unique  clonotypes.  The  amino-terminal  region  of  PA83 
(PA20) is immunodominant in humans. Although PA20 comprises less than 25% of the mass of the 
monomer, over 60% of the PA-specific antibody response recognizes epitopes associated with this 
region. This epitope dominance has been demonstrated in both the polyclonal human serum response 
following  vaccination,  and  in  the  monoclonal  antibodies  isolated  from  vaccinated  donors  [4]. 
Individual  antibodies capable of neutralizing lethal toxin (LT) in  vitro are relatively infrequent in 
vaccinated individuals, and constitute only about 24% of the PA-specific paratopes isolated. And, 
although neutralizing paratopes occur less frequently and are less effective among those individual 
antibodies recognizing PA20-associated epitopes, the immuno-dominance of this region results in a 
significant portion of the post vaccination LT-neutralizing potential of the antibody response being 
derived from PA20-specific paratopes [3].  
PA83 is cleaved very rapidly in the host into free PA20 and cell-associated PA63 (which further 
associates to form PA441). Given that PA20 plays no direct role in LT-mediated toxicity, the presence of 
neutralizing  epitopes  in  this  region  of  the  molecule  is  somewhat  unexpected.  In  this  report  we 
determine the mechanism by which a human monoclonal antibody specific for PA20 neutralizes lethal 
toxin in an in vitro assay of cytotoxicity. As has been demonstrated for a murine monoclonal with 
similar binding and neutralization characteristics [7], this human antibody neutralizes LT by blocking 
the requisite cleavage of PA20 from the remainder of the PA monomer. Unlike murine monoclonal 
antibodies, the epitope recognized by this human monoclonal is distant from the furin recognition 
sequence in domain 1 of PA. 
2. Materials and Methods 
2.1. Human Monoclonal Antibody 
Isolation  of  the  PA-specific  monoclonal  antibody  47F12  from  an  AVA-vaccinated  donor  by 
repertoire cloning has been previously described [4]. This antibody was isolated as a recombinant FAB Toxins 2011, 3 
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fragment in E. coli and subsequently expressed as an IgG1 antibody in CHO cells. Secreted antibody 
was concentrated from supernatant, quantitated by capture ELISA, and used in all subsequent assays. 
Other human monoclonal antibodies isolated from the same study were used as controls. These include 
1A5  (PA63-specific,  neutralizing),  11A11  (PA20-specific,  non-neutralizing),  9G5  (PA20  specific,  
non-neutralizing), 4A12 (D4-specific, neutralizing), and 24B1 (PA63-specific, neutralizing). 
2.2. Construction of PA20- and D4-GFP Fusion Proteins 
The  PA20  amino-terminal  (residues  1–191)  and  the  domain  4  (D4)  carboxy-terminal  (residues  
587–735) portion of the PA monomer were cloned using PCR and expressed fused to intact green 
fluorescent  protein  (GFP).  Cloning  primers  for  the  amino-terminal  fragment  were 
ATATGAATTCTATGGAAGTTAAACAGGAGAACCG  (5')  and  ATATGGATCCTCCTTCTA-
CCTCTAATGAATC  (3').  Cloning  primers  for  the  D4  region  were  GCATTAGAATTCGCATCA 
CCATCACCATCACATGAATATTTTAATAAGAGATAAACG (5') and CGTATATCTAGAAGG-
ATCCCCTATC TCATAGCCTTTTTTAGAAAAGAT (3'). Fusion proteins were expressed in E. coli 
and purified by nickel-chelate chromatography.  
2.3. Domain Specificity of PA-Specific Antibodies 
The domain specificity of 47F12 was determined using dot blots. PA and PA-derived proteins were 
spotted onto nitrocellulose membranes using a 96-well manifold. The resulting membrane was then cut 
into strips containing one spot for each protein. Antibodies were incubated with the blots for 2 h at 
37 ° C, washed, and binding visualized by means of an alkaline-phosphatase conjugated goat antibody 
specific for human lambda light chains followed by BCIP/NBT color development. 
2.4. In vitro Toxin Neutralization Assay 
PA and LF were purchased from List Biological Laboratories, Carlsbad, CA. RAW 264.7 cells were 
plated at 4 ×  10
4 cells per well (in 65 μL assay medium) in Nunclon Delta 96-well plates and incubated 
at 37 ° C, 5% CO2 for approximately 4 to 5 h to ensure proper settling and attachment. Antibodies and 
PA/LF were pre-incubated in Greiner Bio-One 96-well plates at 37 ° C, 5% CO2 for 1 h, and then were 
transferred to the 96-well plate containing RAW 264.7 cells. The plate was then placed back into the 
incubator at 37 ° C, 5% CO2 for overnight incubation. The following morning, 20 μL Cell-Titer Blue 
reagent (Promega) was added to each well of the assay plate. Optical density (at 570/595 nm) was 
determined for each well four hours later using a microtiter plate reader. 
2.5. Domain-Specific Blockade of Neutralizing Antibodies in the RAW Cell Assay 
Neutralizing antibodies were pre-incubated with modified forms of PA to verify the specificity of 
the antibody-PA binding in the toxin neutralization assay. PA20 (residues 1–191) was expressed fused 
to GFP as described above and in [3]. A non-functional mutant of PA (PArb-) was constructed using 
QuickChange™ Mutagenesis (Stratagene) by mutating two residues in the D4 region of wild type PA 
(N682A and D683A) to remove its ability to bind to the cell surface receptor. This modification was 
necessary  to  prevent  PA  added  to  the  assay  as  an  inhibitor  from  participating  in  Toxins 2011, 3 
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LF-mediated  toxicity.  Neutralizing  antibodies  were  incubated  with  the  modified  PA  constructs 
overnight at concentrations sufficient for 50% inhibition of LT-mediated cytotoxicity. These were then 
added to the neutralization assay described above, and the degree to which the pre-incubation blocked 
the antibodies ability to neutralize toxin was calculated. 
2.6. Furin Digestion 
To determine the ability of PA20-specific monoclonal antibodies to inhibit the proteolytic cleavage 
of PA by furin, 
125I-PA was incubated with individual monoclonal antibodies for 1 h at 37 ° C followed 
by purification of the antibody-PA complexes with Protein A magnetic beads. Complexed 
125I-PA was 
incubated with furin (New England Biolabs) in the appropriate buffer (100 mM tris, pH 7.5, 0.5% 
Triton X-100, 1 mM CaCl2, 1 mM 2-mercaptoethanol) for 10 min at 37 ° C. Loading buffer was then 
added to each sample, the samples subjected to SDS-PAGE, and the size of the separated 
125I-PA 
determined using a phosphoimager. 
2.7. 
125I-PA Recovery Assay 
RAW 264.7 cells were plated at 5 ×  10
5 cells per well in 24-well plates and incubated at 37 ° C, 5% 
CO2 overnight. Antibodies to be tested, 
125I-PA, and LF were pre-incubated in tubes at 37 ° C for 1 h 
and then were transferred into the 24-well plate containing RAW 264.7 cells. The plate was then 
placed back into the incubator at 37 ° C, 5% CO2 for 1 h (cell lysis begins at approximately 3 h). Media 
was then aspirated from each well, adherent cells washed 5 times with medium, and lysed in 0.150 mL 
lysis buffer (1%NP-40, 0.25% Sodium deoxycholate, 150 mM NaCl, 1 mM EDTA, 2 mM MgCl2 in 
Tris-HCL  pH  7.4).  Lysis  buffer  was  then  collected  from  each  well  and  subjected  to  SDS-PAGE 
analysis as described above for the furin digest assay. 
2.8. Epitope Mapping Using Yeast Display 
PA20, truncated derivatives of PA20, and randomly mutated PA20 were displayed on the surface of 
yeast as Aga2 fusion proteins as described by Boder and Wittrup [8]. The vector pYD1 and the host 
yeast strain EBY100 were purchased from Invitrogen (Carlsbad, CA, USA). PA20 (residues 1–191) and 
truncated  PA20  (residues  1–140)  were  amplified  by  PCR  and  inserted  into  the  BamH  I/  Xho  I 
restriction sites in pYD1 (in frame with AGA2 and separated from it by a flexible linker). Randomly 
mutated libraries of PA20 were generated by error-prone PCR. MnCl2 concentration were titrated, and 
conditions selected such that the average number of amino acid substitutions per molecule ranged from 
1 to 3. These fragments were ligated into pUC18, expanded in E. coli, excised, and inserted into the 
BamH I/ Xho I restriction sites of pYD1. Following sequence verification, yeast were transformed 
with the plasmid, expanded overnight at 30 ° C, transferred into Galactose-containing YNB medium 
(Yeast  Nitrogen  Base  w/o  amino  acids  (Difco))  to  induce  recombinant  protein  expression,  and 
incubated for 48 h at 20 ° C. For PA20 and the truncated derivatives of PA20, yeast were allowed to bind 
to the 47F12 antibody, and binding detected by a secondary phycoerythrin-conjugated anti-light chain 
antibody followed by flow cytometry. For the randomly mutated libraries, bulk yeast cultures were 
stained with 47F12 and a second non-competing PA20 specific antibody. Cell sorting was performed to Toxins 2011, 3 
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select those yeast clones that had lost the ability to bind 47F12 but retained binding to the second 
antibody (this verifies surface expression of the construct). These clones were re-grown, their binding 
profiles  verified,  and the sequence of the PA20 insert  they  contained determined to identify those 
substitutions that had resulted in the loss of the 47F12 epitope. Approximately 40 binding loss mutants 
were analyzed to identify the 47F12 epitope. Residues comprising the epitope were mapped onto the 
surface  of  the  solved  structure  of  PA  [9].  The  region  containing  the  furin  recognition  sequence 
(residues 162–174) is not resolved in the solved structure, and was modeled using the SWISS-MODEL 
homology server for inclusion in Figure 7 [10]. 
2.9. Antibody Concentration and Binding Assays 
Antibody concentration was determined by a capture ELISA in which goat anti-human Fc (The 
Binding Site, Birmingham, UK) immobilized on a microtiter plate captures IgG, which is then detected 
by alkaline-phosphatase labeled goat  anti-human L chain (Biosource International, Camarillo,  CA, 
USA). This assay is standardized using a purchased IgG1 protein standard (Sigma). PA binding in 
ELISA  was  determined  for  IgG1  antibodies  on  96-well  plates  coated  with  5  μg/mL  PA83  and 
developed with alkaline-phosphatase conjugated goat antibody specific for human lambda light chains. 
The Diphtheria toxin mutant CRM197 was used as a specificity control for the binding assay. 
3. Results 
The human monoclonal antibody 47F12 was isolated from a donor vaccinated with the currently 
licensed  anthrax  vaccine  (BioThrax)  as  part  of  a  larger  study  of  the  human  PA-specific  antibody 
repertoire [4]. 47F12 binds PA in a concentration dependent manner (Figure 1A) and is specific for an 
epitope in the PA20 amino-terminal region of the molecule (Figure 1B). When tested in the lethal toxin 
neutralization  assay,  the  antibody  neutralized  lethal  toxin  in  a  dose  dependent  manner,  with  50% 
neutralization  (NC50)  occurring  at  230  ng/mL  (Figure  2).  The  maximum  degree  of  neutralization 
achievable in the assay was about 74%. The inability to achieve 100% toxin neutralization in the RAW 
264.7 assay is a characteristic of PA20-specific neutralizing antibodies in general, and may result from 
competition in the assay by free PA20 that is cleaved from PA83 in the course of intoxication. The 
ability  of  47F12  to  neutralize  lethal  toxin  was  specifically  inhibited  both  by  PA83  and  PA20, 
demonstrating that the PA20-associated epitopes recognized in the direct binding assays were also those 
responsible for toxin neutralization (Figure 3). Together these data indicate that the PA-specific human 
monoclonal antibody 47F12 functions to neutralize lethal toxin by binding to an epitope present in the 
PA20 region of the PA monomer. Toxins 2011, 3 
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Figure 1. PA-specific binding and domain specificity of the human monoclonal antibody 
47F12. (A) Concentration dependent binding of 47F12 to immobilized PA (circles) and the 
irrelevant toxin CRM197 (squares) in an ELISA assay; (B) Domain specificity of binding 
by the human monoclonal antibodies 47F12 and 4A12. PA83 and PA63 were purchased 
from List Biological Laboratories. PA20 and domain 4 (D4) were expressed as a fusion 
proteins with GFP and purified in our laboratory. 
 
Figure 2. Neutralization of lethal toxin in the RAW 264.7 cytotoxicity assay by the human 
monoclonal antibody 47F12. 
 
Figure 3. Inhibition of Lethal Toxin neutralization. PA20-specific (47F12) and PA63-specific 
(24B1) neutralizing monoclonal antibodies were incubated with PA20 or PArb- prior to their 
addition to the RAW cytotoxicity assay. The degree to which pre-incubation with the toxin 
components  blocked  the  antibodies’  ability  to  neutralize  lethal  toxin  was  calculated  as  a 
fraction of the neutralization achieved when antibody was pre-incubated with buffer alone. 
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Since PA20 lacks all of the residues involved in cell surface binding, we postulated that the antibody 
achieved toxin neutralization by inhibiting the requisite cleavage of PA20 from the remainder of the 
molecule by furin. In the presence of furin, radio-labeled PA83 is rapidly cleaved at the 166RKKR169 
recognition  sequence  to  yield  PA63  (Figure  4,  lane  1,  2)  [11,12].  When  radio-labeled  PA83  is  
pre-incubated with 47F12, cleavage is significantly reduced (Figure 4, lane 4). Pre-incubation with the 
PA63-specific neutralizing antibody 1A5 does not result in the blockade of furin-mediated cleavage 
(Figure 4, lane 5), nor does incubation with the PA20-specific non-neutralizing antibody 9G5 (Figure 4, 
lane 6). These data indicate that 47F12 does in fact interfere with the furin mediated cleavage of PA83, 
and that this interference is epitope specific, since 9G5, which is also specific for PA20, fails to inhibit 
the enzyme. 
Figure 4. Furin proteolysis of 
125I-PA in vitro. (1) 30 ng 
125I-PA; (2) PA + furin; (3) PA + 
furin  +  EDTA;  (4)  PA  pre-incubated  with  PA20-specific  neutralizing  antibody  47F12;  
(5) PA pre-incubated with PA63-specific neutralizing antibody 1A5; (6) PA pre-incubated 
with PA20-specific non-neutralizing antibody 9G5. 
 
To determine if 47F12 was functioning in a similar manner in the RAW 264.7 neutralization assay, 
lethal toxin incorporating radio-labeled PA was added to the cultures, recovered following incubation, 
and its size determined using SDS-PAGE (Figure 5). When no antibody was added to the assay, PA63 
(indicating  cleavage),  PA441  (indicating  heptamer  formation),  and  residual  PA83  were  recovered 
following 1 h of incubation (Figure 5, lane 1). Pre-incubation of lethal toxin with 47F12 prior to its 
addition  to  the  assay  results  in  the  recovery  of  PA83  alone,  indicating  that  both  cleavage  and 
subsequent  heptamer  formation  had  been  inhibited  (Figure  5,  lane  2).  Pre-incubation  with  the  
PA63-specific  neutralizing  monoclonal  antibody  1A5  did  not  block  cleavage,  but  did  inhibit  the 
formation  of  the  441-kDa  heptamer  (Figure  5,  lane  3).  Pre-incubation  of  lethal  toxin  with  the  
non-neutralizing,  PA20-specific  antibody  11A11  blocked  neither  cleavage  nor  heptamer  formation 
(Figure 5, lane 4). These data indicate that 47F12 blocks the furin-mediated cleavage of PA83 required 
for lethal toxin-mediated cytotoxicity in the RAW 264.7 neutralization assay, and that this inhibition is 
epitope specific as well, since the PA20-specific non-neutralizing antibody 11A11 did not interfere  
with proteolysis. Toxins 2011, 3 
 
 
986 
Figure 5. Analysis of 
125I-PA recovered from in vitro RAW cell culture. (1) Lethal toxin 
alone  added  to  cell  culture;  (2)  Lethal  toxin  pre-incubated  with  the  PA20-specific 
neutralizing  antibody  47F12  prior  to  addition  to  the  cell  culture;  (3)  Lethal  toxin  
pre-incubated  with  the  PA63-specific  neutralizing  antibody  1A5;  (4)  Lethal  toxin  pre-
incubated with the PA20-specific non-neutralizing antibody 11A11; (5) 1 ng 
125I-PA. 
 
To determine if the epitope recognized by 47F12 encompassed the 166RKKR169 furin recognition 
sequence, a truncated deletion mutant of PA20 was constructed, displayed on the surface of yeast, and 
tested for antibody binding using flow cytometry. The ability of 47F12 to bind to a fragment of PA20 
that was truncated at residue 140 did not differ from binding to the full length PA20 domain (Figure 6). 
Therefore,  although  47F12  blocks  cleavage  by  furin  at  the  166RKKR169  recognition  sequence,  the 
epitope recognized by this antibody does not contain the RKKR recognition sequence itself, nor is it 
found within the 27 residue region upstream from the recognition motif.  
Figure 6. Flow cytometric analysis of human monoclonal antibody 47F12 binding to yeast 
cells displaying PA20 or truncated PA20 on their surface. (A) 47F12 binding to yeast cells 
displaying  PA20  (residues  1–191)  on  their  surface;  (B)  47F12  binding  to  yeast  cells 
displaying truncated PA20 (residues 1–140) on their surface. Binding was detected with a 
phycoerythrin-conjugated antibody specific for human lambda light chains. 
 Toxins 2011, 3 
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To  identify  the  PA20  residues  required  for  47F12  binding,  a  yeast  library  displaying  randomly 
mutated PA20 on its surface was screened using flow cytometry and those yeast clones that had lost the 
ability  to  bind  47F12  sorted  and  their  inserts  sequenced.  Binding  loss  mutants  were  selected  for 
analysis only if they retained the ability to bind the non-competing antibody 18C12. This verifies that 
loss of 47F12 binding is not due to a mutation that blocks surface expression of the PA20 molecule. 
Analysis of 40 binding loss mutants identified substitutions at residues E95, N98, A100, N104, and I106 
that resulted in the loss of affinity of PA20 for 47F12. When mapped to the solved structure of PA, 
these  residues  were  co-located  on  the  surface  of  the  molecule  and  distant  from  the  166RKKR169 
recognition sequence (Figure 7). 
Figure 7. Residues recognized by the the human monoclonal antibody 47F12 mapped onto 
the  solved  structure  of  PA83  [9].  The  PA20  region  of  the  monomer  is  in  yellow,  the 
remainder of the monomer is in gray, residues comprising the epitope (E95, N98, A100, N104, 
I106) highlighted in orange, and the furin recognition site shown in blue. 
 
4. Discussion and Conclusions  
The  mechanism  by  which  antibodies  neutralize  lethal  toxin  is  not  completely  understood. 
Neutralizing  and  non-neutralizing  epitopes  are  distributed  throughout  the  PA  monomer,  and  the 
majority of neutralizing epitopes recognized by vaccinated humans reside in regions other than those 
involved with receptor interactions, implying that the general assumption [13,14] that neutralizing 
antibodies block PA’s ability to bind to its cognate receptor is incomplete. The additional discovery 
that the majority of individual PA-specific antibody clonotypes do not neutralize toxin in spite of avid 
antigen binding suggest that it is the specific epitope bound, rather than overall affinity for the antigen, 
that determines an antibodies’ ability to neutralize toxin function [3]. The mechanism by which the 
majority of toxin neutralization is realized therefore remains to be determined. 
The series of events required for lethal toxin to result in cell death is complex [1,2,15–17]. PA must 
bind to the cell surface, undergo proteolytic cleavage, heptamerize to form the pre-pore, bind lethal 
factor  (LF),  insert  into  the  membrane,  and  be  endocytosed.  It  is  likely  that  antibody-mediated 
neutralization  involves  the  disruption  of  one  or  more  of  these  requisite  steps  in  the  intoxication 
process. Neutralizing antibodies within the PA20-specific portion of the antibody repertoire are both 
infrequent  and  much  less  efficient  than  those  recognizing  PA63,  but  they  are  nevertheless  well Toxins 2011, 3 
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represented due the overall immunodominance of PA20-associated epitopes in the human response [4]. 
This report demonstrates that the monoclonal antibody 47F12 blocks the ability of furin to cleave, and 
thereby activate, PA. Although the PA20 peptide itself has no known role in toxicity, its proteolytic 
removal is an absolute requirement for PA heptamerization and LF binding [18]. Other PA20-specific 
neutralizing antibodies may function by interfering with other steps in the intoxication pathway. For 
example, following cleavage, PA20 remains non-covalently associated with PA63, and this association 
must be disrupted in order for those residues involved in the self-assembly of the heptamer to be 
exposed  [9].  An  antibody  that  blocked  the  disassociation  of  PA20  from  PA63  may  also  inhibit 
intoxication without blocking furin cleavage directly. We have identified two additional neutralizing 
epitopes  within  PA20  recognized  by  human  PA-specific  monoclonal  antibodies,  neither  of  which 
include the 166RKKR169 recognition sequence. The mechanism by which these antibodies neutralize PA 
has not yet been determined. 
The relative contribution of antibodies specific for different regions of the PA monomer to toxin 
neutralization in vivo is unknown. In animal models, both PA20 and PA63 have been shown to circulate 
following  infection  [19,20],  and  it  is  reasonable  to  assume  that  antibodies  specific  for  these  two 
regions  would complex with  their respective epitopes  in  the circulation. The implications  for  this 
complex formation on toxin neutralization differ, however, according to the region of the molecule 
bound.  Antibodies  specific  for  PA20-associated  epitopes  can  only  effect  neutralization  while  PA20 
remains associated with PA63. Circulating PA20 would therefore compete with cell-bound PA20 for 
neutralizing paratopes, thereby lowering the overall efficacy of antibodies directed against neutralizing 
epitopes in the amino-terminal region of the PA monomer. Neutralizing antibodies binding circulating 
PA63 would, on the other hand, impede toxicity whether the determinants are encountered in solution 
or at the cell surface. The in vivo performance of the murine PA20-specific monoclonal 7.5G, which 
efficiently neutralizes lethal toxin in vitro, but is only modestly effective in vivo, would support this 
hypothesis  [7].  The  paucity  of  neutralizing  paratopes  within  the  immuno-dominant  PA20-specific 
portion of the response, the relative inefficiency of those that do occur, and their susceptibility to 
inhibition by circulating PA20 in the host, when considered together, may partially account for the 
relatively poor performance of AVA in vaccine recipients. 
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